Deciphera Pharmaceuticals LLC
1505 Wakarusa Drive
Lawrence
Kansas
66047
Tel: 785-838-3767
Fax: 785-838-3747
Website: http://www.deciphera.com/
Email: deciphera@deciphera.com
238 articles about Deciphera Pharmaceuticals LLC
-
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results
5/3/2023
Deciphera Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.
-
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
4/26/2023
Deciphera Pharmaceuticals, Inc. today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023.
-
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
4/19/2023
Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on Wednesday, April 26, 2023 at 10:30 AM ET.
-
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients & FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 & 17/18
3/14/2023
Deciphera Pharmaceuticals, Inc. announced that QINLOCK® has been included in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology as a preferred regimen for second-line gastrointestinal stromal tumor patients intolerant to sunitinib.
-
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
3/14/2023
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of eight posters at the upcoming AACR Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023.
-
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
3/1/2023
Deciphera Pharmaceuticals, Inc. today announced the completion of enrollment in the pivotal Phase 3 MOTION study of vimseltinib in patients with tenosynovial giant cell tumor (TGCT) not amenable to surgery. Deciphera expects to report top-line results in the fourth quarter of 2023.
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - February 27, 2023
2/27/2023
Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences.
-
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
2/7/2023
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
2/2/2023
Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in fireside chats at the following investor conferences.
-
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
1/31/2023
Deciphera Pharmaceuticals, Inc. today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023.
-
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
1/24/2023
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the presentation of additional data from the planned exploratory analysis from the INTRIGUE Phase 3 clinical study of QINLOCK® using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib.
-
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
1/24/2023
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announced the closing of its underwritten public offering of 7,986,111 shares of its common stock.
-
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Jan 20, 2023
1/20/2023
Deciphera Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00 per share.
-
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock - Jan 18, 2023
1/18/2023
Deciphera Pharmaceuticals, Inc. announced that it intends to offer and sell $125,000,000 of shares of its common stock in an underwritten public offering.
-
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 9:45 AM PT.
-
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
1/3/2023
Deciphera Pharmaceuticals, Inc. announced findings of a planned exploratory analysis of data from the INTRIGUE Phase 3 clinical study of QINLOCK using circulating tumor DNA from a subgroup of patients with gastrointestinal stromal tumor previously treated with imatinib who harbor mutations in KIT exon 11 and 17/18 only.
-
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
1/3/2023
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, highlighted its strategic outlook for 2023 and planned 2023 corporate milestones, and announced preliminary unaudited fourth quarter and full year 2022 revenue.
-
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
12/1/2022
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 6, 2022 at 10:40 AM ET.
-
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming November 2022 Investor Conferences
11/8/2022
Deciphera Pharmaceuticals, Inc. announced that members of the management team will participate in fireside chats at the following investor conferences.
-
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
11/3/2022
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.